209860-87-7

Basic information

• Product Name: Tafluprost
• Synonyms: 15,15-DIFLUORO-9ALPHA,11ALPHA-DIHYDROXY-16-PHENOXY-17,18,19,20-TETRANOR-PROSTA-5Z,13E-DIEN-1-OIC ACID, ISOPROPYL ESTER;AFP-168;TAFLUPROST;(5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid 1-methylethyl ester;Tafluprost5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-,1-methylethyl ester, (5Z)-;209860-87-7
• CAS NO: 209860-87-7
• Molecular Formula: C25H34F2O5
• Molecular Weight: 452.53
• Mol File: 209860-87-7.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 552.9ºC at 760mmHg
• Flash Point: 288.2°C
• Appearance: /
• Density: 1.186
• Vapor Pressure: 4.62E-13mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: 2-8°C
• PKA: 14.48±0.70(Predicted)
• CAS DataBase Reference: Tafluprost(CAS DataBase Reference)
• NIST Chemistry Reference: Tafluprost(209860-87-7)
• EPA Substance Registry System: Tafluprost(209860-87-7)

Safety Data

• Hazardous Substances Data: 209860-87-7(Hazardous Substances Data)

Usage

Description

Glaucoma is second only to cataracts as a causative factor of blindness. By 2010, it is estimated that approximately 60 million people worldwide will be afflicted by glaucoma, so effective treatments should garner a large market. PG analogs have been widely used for lowering IOP by increasing uveoscleral outflow through agonism of the prostanoid FP receptor, and currently marketed versions include latanoprost, unoprostone isopropyl ester, bimatoprost, and travoprost. Compared to the carboxylic acid of latanaprost (Ki=4.7 nM), the carboxylic acid of tafluprost displayed a 10-fold greater affinity for the prostanoid FP receptor (Ki=0.4 nM). The synthesis of tafluprost begins with a Wittig condensation of the protected bicyclic lactone carbaldehyde with a dimethyl phosphonate ketone derivative.Compared to the carboxylic acid of latanaprost (Ki 4.7 nM), the carboxylic acid of tafluprost displayed a 10-fold greater affinity for the prostanoid FP receptor (Ki 0.4 nM). The synthesis of tafluprost begins with a Wittig condensation of the protected bicyclic lactone carbaldehyde with a dimethyl phosphonate ketone derivative. The bottom appendage is then completed by the fluorination of the ketone with morpholino-sulfur trifluoride. Hydrolysis of the benzoate ester protecting group liberates the hydroxy group, and reduction of the lactone is accomplished with aluminum hydride to generate the lactol. Condensation of this intermediate with the phosphonium salt of the acid side chain generates the free acid, or active ingredient, which is subsequently esterified with 2-iodopropane in the presence of DBU. .

Originator

Santen/Asahi Glass (Japan)

Uses

Tafluprost is a novel prostanoid used in the treatment of glaucoma and is the first prostanoid to be released in a preservative free-formula.

Definition

ChEBI: A prostaglandin Falpha that is prostaglandin F2alpha in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side- hain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Brand name

Taflotan

Synthesis

The synthesis was initiated from the Corey aldehyde 131. Horner-Emmons condensation of the bicyclic carbaldehyde 131 with the dimethyl phosphonate 132 using NaH in DMF gave enone 133 in 90% yield. Fluorination of the enone 133 was accomplished upon reaction with morpholino-sulfur trifluoride (134) in chloroform to yield the corresponding difluorinated compound 135. Hydrolysis of the benzoate ester group of 135 with K2CO3 in methanol at room temperature afforded alcohol 136 in 71% yield from 133. Reduction of the lactone group of 136 with diisobutyl aluminum hydride (DIBAL) in THF/toluene gave lactol 137 in 83% yield. Lactol 137 was condensed with the phosphonium ylide prepared by deprotonation of phosphonium salt 138 with sodium bis(trimethylsilyl)amide (NaHMDS) in THF/toluene to give the prostaglandin F2-alpha derivative 139 in excellent Z/E selectivity (99:1). The synthesis was completed by esterification of compound 139 with isopropyl iodide and DBU in acetone to provide tafluprost (XVIII) in 72% yield.

InChI:InChI=1/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3+,15-14+

Upstream product

• 75-30-9 2-iodo-propane 
• 209860-88-8 AFP-172 
• 163074-98-4 [(3aR,4R,5R,6aS)-hexahydro-2-oxo-5-(phenylmethoxy)-2H-cyclopenta[b]furan-4-carboxaldehyde] 
• 81190-06-9 [(3aR,4S,5R,6aS)-hexahydro-4-(hydroxymethyl)-5-(phenylmethoxy)-2H-cyclopenta[b]furan-2-one] 
• 29782-85-2 rac-(trans)-2,2-dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-ol 
• 1487-05-4 rac-(trans)-3,3-dimethyltetrahydro-5H-oxireno[2',3':3,4]cyclopenta[1,2-d][1,3]dioxole 
• 5623-52-9 rac-2,2-dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxole 
• 542-92-7 cyclopenta-1,3-diene 
• 7129-41-1 6-oxabicyclo<3.1.0>hex-2-ene 

Relevant articles and documents

Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: A novel 15-deoxy-15,15-difluoroprostaglandin F2α derivative

A novel 15-deoxy-15,15-difluoro-prostaglandin(PG)F2α derivative 6 (AFP-168) has been synthesized from the Corey aldehyde in six steps. A key aspect of this route is difluorination of an enone and a stereoselective Wittig reaction. The compound shows high affinity to the FP receptor and potent activities for an anti-glaucoma agent.

Method for large-scale preparation of tafluprost

The invention discloses a method for industrially preparing tafluprost. The method comprises the following steps: taking Corey lactone as an initial raw material, oxidizing, condensing, fluorinating,deprotecting, reducing, re-condensing, esterifying and r

Crystal form of metallic salt compound of Tafluprost acid and preparation method of crystal form

The invention relates to a crystal form of a metallic salt compound of Tafluprost acid and a preparation method of the crystal form. Specifically, the invention relates to the crystal form of the metallic salt compound of Tafluprost acid, the preparation method of the crystal form and a method for preparing Tafluprost from the metallic salt compound of Tafluprost acid. According to the method, reaction yield is increased, isomer impurities are reduced, and the method is simple and easy to control and facilitates industrial expanded production.